Mesoblast LtdMESO

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$15.48
Market cap
$2.0B
P/E
—
Revenue (FY)
$17.2M
Net income
-$102.1M
Dividend yield
—
1-year total return
-5.1%
Net margin
-593.9%
Revenue growth
191.4%
Debt / equity
0.11x

What Mesoblast Ltd does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$32.2M$7.4M$10.2M$7.5M$5.9M$17.2M
Net income-$77.9M-$98.8M-$91.3M-$81.9M-$88.0M-$102.1M
Free cash flow———-$63.5M-$48.7M-$50.6M

More on MESO.

Figures from Mesoblast Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.